Alpharma Inc. (NYSE: ALO) presented results of a Phase IV study of KADIAN (morphine sulfate extended-release) Capsules that demonstrate the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE